| ORUKA THERAPEUTICS INC. |
| USA |
| Gesundheit |
| US6876041087 / A3DPH3 |
| HQ1 (Frankfurt) / ORKA (NASDAQ) |
| FRA:HQ1, ETR:HQ1, HQ1:GR, NASDAQ:ORKA |
| - |
| https://orukatx.com/ |
|
Oruka Therapeutics, Inc. is a clinical-stage biotechnology company specializing in the development of novel monoclonal antibody therapeutics aimed at treating chronic inflammatory and immune-mediated ..
>Volltext.. |
| 1445.63 Mio. EUR |
| 1150.92 Mio. EUR |
| - |
| -102.29 Mio. EUR |
| -88.2 Mio. EUR |
| -2.1 EUR |
| 1.66 Mio. EUR |
| 79.19 Mio. EUR |
| -73.28 Mio. EUR |
| 16.65 |
| - |
| -180.33% |
| - |
| - |
| - |
| ORUKA |
| 13.03.26 |
|